Trial
NCT01162031
Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Stanford University
Collaborators
Millennium Pharmaceuticals, Inc.
Condition
Leukemia
Intervention
Velcade
Why stopped
no accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-05-21